BeneHold™ CHG Antimicrobial Adhesive Technology

The skin is home to trillions of bacteria, which are mostly harmless until introduced inside the body where they can cause infection.  Scientists at Avery Dennison Medical have developed the BeneHold™ CHG antimicrobial adhesive to help with this problem. Chlorhexidine Gluconate (CHG) was chosen because it is a well-documented broad-spectrum antiseptic already widely used in many medical products to minimize microbial growth, including coated central venous catheters, skin antiseptics and IV site dressings.

BeneHold™ CHG adhesive technology by Avery Dennison Medical delivers the functionality of this antimicrobial agent in a thin acrylic adhesive layer that can be customized for various applications and performance requirements. We focus on adding antimicrobial properties to the primary skin contact layer; therefore eliminating the need for an additional component that holds and delivers the antimicrobial agent. In addition, BeneHold™ CHG adhesive technology when coupled with a transparent carrier film allows the contact layer to remain transparent and thin, making it easy to observe the site without disturbing it and offering added comfort. This novel adhesive technology is the subject of  several granted patents globally and a number of pending applications. 

 


Features and Benefits

BeneHold™ CHG adhesive technology is a unique proprietary acrylic-based adhesive with the following important properties:

  1. In vitro testing demonstrated that BeneHold™ CHG has an antimicrobial effect against a variety of gram-negative and gram-positive bacteria and yeast.1

  2. The absorptive properties of BeneHold™ CHG manage fluids such as blood, perspiration and other exudates providing a moist environment ideal for wound healing.

  3. When BeneHold™ CHG is applied to a breathable carrier,  absorbed fluid is released through the film by vapor exchange for additional fluid handling capacity.

  4. The BeneHold™ CHG adhesive remains transparent throughout use and when coupled with a transparent carrier film it allows for continuous visual monitoring of site conditions.

  5. The CHG adhesive has been found to be non-cytotoxic and safe to use.


How does CHG work?

CHG (Chlorhexidine Gluconate) is highly soluble; and in physiologic conditions it readily dissociates to release catonic chlorhexidine molecules into solution. 

CHG molecules, that are positively charged, strongly bind to negatively charged bacterial cell walls. This damages the bacteria’s surface structure leading to an osmotic imbalance. The consequent precipitation of cytoplasm causes cell death.2  The following video demonstrates this process in action.


Commercial Products

The BeneHold CHG adhesive technology is designed to address applications requiring long wear time and sustained antimicrobial efficacy (up to 7 days) and is featured in several commercialized products:


Vascular Access

The innovative BD ChloraShield™ IV dressing with CHG antimicrobial is designed to uniquely address some of the limitations of standard IV catheter dressings, including antimicrobial efficacy and moisture management:

  • BeneHold™ adhesive technology formulated with CHG provides sustained antimicrobial activity against skin flora for up to 7 days.3
  • Thin, flexible material is easy to apply and remove.
  • Offers high fluid handling capacity due to the absorptive properties of the CHG adhesive and the breathability of the film carrier.
  • Provides a barrier to external contaminants.
  • Is non-cytotoxic and minimally irritating to the skin.
  • Available in a variety of designs for both PICC and PIV applications, as well as a specially designed dressing for the BD Nexiva™ Closed IV Catheter System.

To learn more visit: http://bd.com/chlorashield

ChloraShield™ IV Dressing with CHG antimicrobial​, exclusively marketed and distributed by BD (Becton, Dickinson and Company) (NYSE: BDX).

Precautions:

The dressing should not be placed over infected wounds. This device is not intended to treat catheter-related bloodstream infections (CRBSIs) or other percutaneous device-related infections. This device has not been studied in a randomized clinical study to determine its effectiveness in preventing such infections.

Active bleeding at insertion sites should be stabilized before applying the dressing.

Do not stretch the dressing before applying it to the skin. Dressings applied under tension can cause trauma to the skin.

To ensure good adhesion and to help prevent skin irritation, remove detergent residues and allow all skin preparations and protectants to dry completely before applying the dressing to the skin.

For proper use, clinicians should be trained in the use of this device.

Warnings:

  • DO NOT USE BD CHLORASHIELD™ IV DRESSING WITH CHG ANTIMICROBIAL ON PREMATURE INFANTS OR INFANTS YOUNGER THAN 2 MONTHS OF AGE. USE OF THIS PRODUCT ON PREMATURE INFANTS MAY RESULT IN HYPERSENSITIVITY REACTIONS OR NECROSIS OF THE SKIN.
  • FOR EXTERNAL USE ONLY. DO NOT ALLOW CONTACT OF THIS DEVICE WITH EARS, EYES, MOUTH OR MUCOUS MEMBRANES.
  • DO NOT USE THIS DEVICE ON PATIENTS WITH A KNOWN HYPERSENSITIVITY TO CHLORHEXIDINE GLUCONATE. ADVERSE REACTIONS SUCH AS IRRITATIONS, SENSITIZATION AND GENERALIZED ALLERGIC REACTIONS HAVE BEEN REPORTED WITH THE USE OF CHLORHEXIDINE GLUCONATE.
  • STOP USING THE BD CHLORASHIELD™  DRESSING WITH CHG ANTIMICROBIAL IF THE PATIENT EXPERIENCES SYMPTOMS SUCH AS: WHEEZING OR DIFFICULTY BREATHING, SWELLING FACE, HIVES THAT CAN QUICKLY PROGRESS TO MORE SERIOUS SYMPTOMS, SEVERE RASH OR SHOCK (WHICH IS A LIFE THREATENING CONDITION THAT OCCURS WHEN THE BODY IS NOT GETTING ENOUGH BLOOD FLOW). THESE SYMPTOMS ARE ASSOCIATED WITH AN ALLERGIC REACTION TO CHG.
  • Literature searches found hypersensitivity reactions associated with the topical use of chlorhexidine gluconate have been reported in several countries. Caution should be used when using chlorhexidine containing preparations, and the patient should be observed for the possibility of hypersensitivity reactions.
  • IF ALLERGIC REACTIONS OCCUR, DISCONTINUE USE IMMEDIATELY AND, IF SEVERE, CONTACT A PHYSICIAN.
  • Do not use on immune compromised patients or patients with underlying skin pathology which compromises the epidermal barrier. Use of this product may result in erosive contact dermatitis.
  • INTENDED FOR SINGLE PATIENT USE ONLY.
  • DO NOT REUSE. AS WITH ALL ADHESIVE-BASED PRODUCTS, ADHESIVE EFFECTIVENESS AND FUNCTIONALITY CAN DECLINE AFTER THE FIRST USE AND THE PRODUCT WILL NOT PERFORM AS SPECIFIED. REUSE MAY LEAD TO INFECTION OR OTHER ILLNESS/INJURY.
  • STORE IN COOL, DRY PLACE. KEEP AWAY FROM DIRECT SUNLIGHT. DO NOT STORE ABOVE 25°C/77°F. DO NOT USE IF PACKAGING IS DAMAGED. DO NOT RESTERILIZE.

Post-Operative Dressings:

ReliaTect® Post-Op Dressing with CHG is a sterile, post-op dressing consisting of a polyurethane film coated with BeneHold™ CHG adhesive technology. The ReliaTect® Post-Op Dressing with CHG was designed to meet many of the unmet needs of typical post-operative dressings:

  • The ReliaTect® Post-Op Dressing is coated with an acrylic adhesive formulated with CHG, which preserves the dressing and has been shown to sustain antimicrobial activity against skin flora for up to seven days.2
  • The non-woven border of the ReliaTect® Post-Op Dressing facilitates dressing application and provides additional securement during wear.
  • ReliaTect® Post-Op Dressing offers a unique combination of transparency and absorbency while providing a barrier to external contaminants; and can be worn up to 7 days.
  • The ReliaTect® Post-Op Dressing is non-cytotoxic and non-irritating to the skin.

To learn more visit: http://eloquesthealthcare.com/reliatect-post-op

ReliaTect® Post-Op Dressing with CHG​, marketed and distributed in the U.S.A. and Canada  by Eloquest Healthcare, Inc., a wholly owned subsidiary of Ferndale Pharma Group, Inc.

Precautions: 

The dressing should not be placed over infected wounds. This device is not intended to treat Surgical Site Infections (SSl's) or other percutaneous device-related infections. This device has not been studied in a randomized clinical study to determine its effectiveness in preventing such infections.

Active bleeding at wound sites should be stabilized before applying the dressing.

Do not stretch the dressing before applying it to the skin. Dressings applied under tension can cause trauma to the skin.

To ensure good adhesion and to help prevent skin irritation, remove detergent residues and allow all skin preparations and protectants to dry completely before applying the dressing to the skin.

Caution: Federal (USA) law restricts this device to sale by or on the order of a licensed healthcare practitioner.

For proper use, clinicians should be trained in the use of this device.

Warnings:

  • ReliaTect® Post-Op Dressing with CHG SHOULD NOT BE USED AS A REPLACEMENT FOR SUTURES AND OTHER PRIMARY WOUND CLOSURE METHODS.
  • ReliaTect® Post-Op Dressing with CHG SHOULD NOT BE USED ON THIRD DEGREE BURNS.
  • DO NOT USE ReliaTect® Post-Op Dressing with CHG ON PREMATURE INFANTS OR INFANTS YOUNGER THAN 2 MONTHS OF AGE. USE OF THIS PRODUCT ON PREMATURE INFANTS MAY RESULT IN HYPERSENSITIVITY REACTIONS OR NECROSIS OF THE SKIN.
  • ReliaTect® Post-Op Dressing with CHG SHOULD NOT BE USED AS A PRIMARY MEANS TO FIX ARTERIAL CATHETERS OR ARTERIAL CANNULAE.
  • FOR EXTERNAL USE ONLY. DO NOT ALLOW CONTACT OF THIS DEVICE WITH EARS, EYES, MOUTH OR MUCOUS MEMBRANES.
  • DO NOT USE THIS DEVICE ON PATIENTS WITH A KNOWN HYPERSENSITIVITY TO CHLORHEXIDINE GLUCONATE. ADVERSE REACTIONS SUCH AS IRRITATIONS, SENSITIZATION AND GENERALIZED ALLERGIC REACTIONS HAVE BEEN REPORTED WITH THE USE OF CHLORHEXIDINE GLUCONATE.
  • IF ALLERGIC REACTIONS OCCUR, DISCONTINUE USE IMMEDIATELY AND, IF SEVERE, CONTACT A PHYSICIAN.
  • STOP USING THE ReliaTect® Post-Op Dressing with CHG IF THE PATIENT EXPERIENCES SYMPTOMS SUCH AS: WHEEZING OR DIFFICULTY BREATHING, SWELLING FACE, HIVES THAT CAN QUICKLY PROGRESS TO MORE SERIOUS SYMPTOMS, SEVERE RASH OR SHOCK (WHICH IS A LIFE THREATENING CONDITION THAT OCCURS WHEN THE BODY IS NOT GETTING ENOUGH BLOOD FLOW). THESE SYMPTOMS ARE ASSOCIATED WITH AN ALLERGIC REACTION TO CHG.
  • Patients must be questioned about any prior allergic reactions to a medical device containing Chlorhexidine Gluconate. ALTERNATIVES MUST BE CONSIDERED UNDER SUCH CIRCUMSTANCES.
  • Literature searches found hypersensitivity reactions associated with the topical use of chlorhexidine gluconate have been reported in several countries. Caution should be used when using chlorhexidine­ containing preparations, and the patient should be observed for the possibility of hypersensitivity reactions.
  • Do not use on immune compromised patients or patients with underlying skin pathology which compromises the epidermal barrier. Use of this product may result in erosive contact dermatitis.
  • INTENDED FOR SINGLE PATIENT USE ONLY.
  • DO NOT REUSE. AS WITH ALL ADHESIVE-BASED PRODUCTS, ADHESIVE EFFECTIVENESS AND FUNCTIONALITY CAN DECLINE AFTER THE FIRST USE AND THE PRODUCT WILL NOT PERFORM AS SPECIFIED. REUSE MAY LEAD TO INFECTION OR OTHER ILLNESS/INJURY.
  • STORE IN A COOL DRY PLACE. KEEP AWAY FROM DIRECT SUNLIGHT. DO NOT STORE ABOVE 25°C/77°F. DO NOT USE IF PACKAGING IS DAMAGED. DO NOT RESTERILIZE.

Our Partners

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD has 65,000 employees and a presence in virtually every country around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com

Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare helps deliver safer, more compassionate care by providing intuitive, cost-effective solutions that aid in the prevention of hospital acquired infections. More information can be found at www.eloquesthealthcare.com.


Opportunities

The BeneHold™ CHG adhesive technology can be customized for a variety of applications and performance requirements. We see possibilities for this technology across many other medical applications including surgical incise drapes, negative pressure wound therapy drapes, and acute and chronic wound care dressings. 

If you are searching for an adhesive solution that offers the additional benefit of an antimicrobial agent, CHG, or you would like more information on how you can take advantage of this unique BeneHold™ CHG adhesive technology, contact Avery Dennison Medical by completing the form below.

We are actively seeking partnership opportunities to expand our post-op dressing into additional geographies; if you are interested please complete the form below and a member of our team will contact you shortly.

References:

  1. Data on file with Avery Dennison.
  2. Denton, Graham. “Chlorhexidine.” In Block, S., editor. Disinfection, Sterilization and Preservation, 5th edition. Philadelphia: Lippincott, Williams & Wilkins, 2001, 321-336.
  3. Carty, N., Wibaux, A., Ward, C., Paulson, D., and Johnson, P. “Antimicrobial activity of a novel adhesive containing chlorhexidine gluconate (CHG) against the resident microflora in human volunteers.” J Antimicrob Chemother, 2014, 69(8):2224-2229.